BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27907054)

  • 1. DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis.
    Dai L; Ma C; Zhang Z; Zeng S; Liu A; Tang S; Ren Q; Sun Y; Xu C
    PLoS One; 2016; 11(12):e0167228. PubMed ID: 27907054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study.
    Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ
    J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis.
    Li FF; Yang Y; Wang XL; Hong YY; Wang NF; Chen ZD
    Tumour Biol; 2014 Jun; 35(6):6011-20. PubMed ID: 24659425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between promoter methylation of DAPK gene and HNSCC: A meta-analysis.
    Cai F; Xiao X; Niu X; Zhong Y
    PLoS One; 2017; 12(3):e0173194. PubMed ID: 28249042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effect of DAPK promoter methylation in gastric cancer: A systematic meta-analysis.
    Jia W; Yu T; Cao X; An Q; Yang H
    Medicine (Baltimore); 2016 Oct; 95(43):e5040. PubMed ID: 27787359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer.
    Zhang J; Yu XL; Zheng GF; Zhao F
    Cancer Biomark; 2015; 15(5):609-17. PubMed ID: 26406950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis.
    Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S
    Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of RARβ2, DAPK, hMLH1, p14, and p15 is associated with progression of breast cancer: A PRISMA-compliant meta-analysis.
    Qi M; Xiong X
    Medicine (Baltimore); 2018 Dec; 97(51):e13666. PubMed ID: 30572486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.
    Li Y; Zhu M; Zhang X; Cheng D; Ma X
    Drug Des Devel Ther; 2015; 9():1785-96. PubMed ID: 25848215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis.
    Wang H; Zhou LY; Guan ZB; Zeng WB; Zhou LL; Liu YN; Pan XY
    PLoS One; 2019; 14(1):e0210943. PubMed ID: 30682070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
    Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.
    Wang Y; Kong CZ; Zhang Z; Yang CM; Li J
    DNA Cell Biol; 2014 Apr; 33(4):205-16. PubMed ID: 24491043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma.
    Hu SL; Kong XY; Cheng ZD; Sun YB; Shen G; Xu WP; Wu L; Xu XC; Jiang XD; Huang DB
    Tumori; 2010; 96(5):726-33. PubMed ID: 21302620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer.
    Christoph F; Hinz S; Kempkensteffen C; Weikert S; Krause H; Schostak M; Schrader M; Miller K
    J Cancer Res Clin Oncol; 2007 Jun; 133(6):343-9. PubMed ID: 17160380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of RAS association domain family Protein1A (RASSF1A) methylation states and bladder cancer risk: a systematic review and meta-analysis.
    Gao T; Wang S; He B; Pan Y; Song G; Gu L; Chen L; Nie Z; Xu Y; Li R
    PLoS One; 2012; 7(11):e48300. PubMed ID: 23139773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of death-associated protein kinase gene and methylation status of promoter region in acute leukemia].
    Niu YM; Wang PP; Wang Y; Wang YZ; Cai DL; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):30-4. PubMed ID: 24598646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reversion transcriptional expression of DAPK in bladder cancer T24 cells 5-aza-2'-deoxycytidine].
    Xu NR; Liu CX; Zheng SB; Li HL; Xu YW; Xu K
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Sep; 29(9):1882-6. PubMed ID: 19778817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Association Between MGMT Promoter Methylation and Patients with Gastric Cancer: A Meta-Analysis.
    Yuan X; Xu J; Fang W; Zhao Z; Wang F; Tong Z
    Genet Test Mol Biomarkers; 2017 Apr; 21(4):213-221. PubMed ID: 28384044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell carcinoma: a systematic review and meta-analysis.
    Don KR; Ramani P; Ramshankar V; Sherlin HJ; Premkumar P; Natesan A
    Indian J Dent Res; 2014; 25(6):797-805. PubMed ID: 25728117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.